This study looks at how safe a medicine called Efruxifermin (EFX) is for people with liver problems like Nonalcoholic Steatohepatitis (NASH) and Nonalcoholic Fatty Liver Disease (NAFLD). These are liver diseases where fat builds up in the liver, not because of drinking alcohol. The study compares EFX with a placebo (a harmless pill that has no medicine) to see which is better.
To join, you must be 18-80 years old (19-80 in Korea) and have 2 of 4 health issues: obesity, high cholesterol, high blood pressure, or high blood sugar. You should not have other liver diseases or unstable diabetes. If you took part in a previous study and got a placebo, you might join an open-label study where everyone gets EFX.
- Study length and number of visits are not specified.
- Participants may receive compensation.
- There may be risks related to the treatment.
How understandable was the trial content above?
Hard to understand
Easy to understand